About Legal CJC-1295.

What this project is

Legal CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed and regulatory research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site exists because CJC-1295 is one of the most misdescribed compounds in the peptide literature — its regulatory standing is widely misunderstood, and the DAC and no-DAC variants are routinely confused. We read the record and render it plainly: what the human pharmacokinetic studies established, where the FDA and WADA lines sit, and which variant a given fact belongs to.

The project has no author persona and no clinical staff. It is a reading of documents — primary studies, a clinical-trial registry entry, and official regulatory materials — presented as a status console rather than as advice. Nothing here speaks for any individual's situation, and nothing here should be read as a recommendation to use, obtain, or avoid the compound.

How we read the record

We borrow one idea from instrument design: surface the state honestly. Every finding on this site is presented with its status. Where the published research establishes something — the multi-day GH and IGF-1 kinetics of the DAC variant, the preserved pulsatility, the receptor mechanism — we say so cleanly and cite it. Where the evidence is absent — long-term safety, controlled efficacy in healthy adults — we flag the gap rather than paper over it.

Every quantitative claim maps to a numbered source on the full reference list. We cite primary studies, the clinical-trial registry, and official regulatory materials. We do not cite vendor pages, and we do not invent figures. When a registry value is genuinely uncertain — as with CJC-1295's exact molecular formula — we say that too.

What the name means

"Legal" in this site's name is editorial framing, not a service claim and not a verdict. It marks the question the site is built around: where CJC-1295 actually stands across the regulatory and anti-doping systems that govern it. The answer the record gives is consistent — unapproved for human use, not recommended for the FDA 503A compounding bulks list at the 2024 PCAC, and prohibited at all times in sport under WADA Section S2.

We do not offer treatment, consultation, or prescriptions, and we are not a pharmacy. The site is a reading of the published science and the public regulatory record — a status console, not a storefront and not a clinic.